TY - JOUR T1 - 850 Clinical management and outcomes of primary ovarian sarcomas – a single center experience JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - A280 LP - A280 DO - 10.1136/ijgc-2021-ESGO.485 VL - 31 IS - Suppl 3 AU - V Theodoulidis AU - DE Vlachos AU - C Theofanakis AU - V Pergialiotis AU - N Thomakos AU - A Rodolakis AU - D Haidopoulos Y1 - 2021/10/01 UR - http://ijgc.bmj.com/content/31/Suppl_3/A280.1.abstract N2 - Introduction/Background*Primary ovarian sarcoma is a very rare malignancy representing <2% of ovarian cancer. Aim of this study is to investigate the clinicopathologic features and outcomes in patients with primary sarcoma of the ovary.Methodology We retrospectively reviewed between 2012 and 2019, all patients with primary ovarian sarcoma who were treated at Alexandra Hospital of Athens.Result(s)*A total of 17 patients with ovarian sarcoma had been surgically treated. The median age of patients was 61 [33-84] years. The most common symptom was abdominal pain and bloating. The majority of patients were postmenopausal (14) and only three were premenopausal. The histopathological diagnosis revealed 14 patients with carcinosarcoma, two with ovarian endometrial stromal sarcoma and one with leiomyosarcoma. After the surgery 23% of patients were at stage I, 12% at stage II, 53% at stage III and 12% at stage IV. Only 5 (29%) patients had suboptimal debulking surgery and 12 (71%) had optimal debulking surgery. The mean number of chemotherapy courses were 6.8 ± 4 with unsatisfactory response. Five patients had a recurrence at two years and 4 of them had a secondary debulking surgery.Conclusion*Primary ovarian sarcoma has a poor prognosis. Optimal debulking surgery appears to be a significant factor for recurrence. There is a need for more studies to explore the role of optimal debulking surgery and adjuvant chemotherapy in primary ovarian sarcoma. ER -